Abbott Laboratories ABT faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising ...

Asalanka made 127 off 126 balls, but took his time initially under sustained pressure before unfurling blistering shots ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...

For fourth-quarter fiscal 2024, Abbott projects ... quarter. The rapid and point-of-care diagnostics businesses are expected to have gained from the continued expansion of test menus and ...

A prehospital blood test may rapidly distinguish between ischemic and hemorrhagic strokes, potentially enabling more timely, ...

Welcome to Abbott’s Fourth Quarter 2024 ... Growth in the quarter was led by rapid diagnostics where excluded COVID testing sales increased 16% in the quarter. This was driven by strong demand ...

Hollywood’s history is filled with legendary comedy teams, each leaving behind a unique imprint on the world of entertainment. Some, like Laurel & Hardy, shared a deep camaraderie that shone through ...